Patent · US Active

Polymorphic forms of metopimazine

US11390620B2 · kind B2 · utility

0Cited by
39References
31Claims
0Family size

Assignee

Inventor

  • Shu Yu · Xiangcheng District, CN

Key dates

Filing dateSep 29, 2020
Grant dateJul 19, 2022
Priority date—
Expiry dateSep 29, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are novel polymorphic forms of metopimazine mesylate. These polymorphic forms are useful in methods, compositions, and kits for the treatment of an enteric nervous system disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.